Abstract
Radioisotope-labeled prostate-specific membrane antigen PET/CT is increasingly used for detection of prostate cancer most often in the setting of biochemical recurrence or in primary staging. This report shows increased PSMA expression in lymph node metastases 3 months after initiation of enzalutamide for castration-resistant prostate cancer, whereas lymph node volume and serum prostate-specific antigen decreases over time. This case demonstrates that increasing F-DCFPyL uptake after initiation of androgen deprivation therapy should not be confused with disease progression.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Diagnosis, Differential
-
Humans
-
Lymphatic Metastasis
-
Lysine / analogs & derivatives
-
Male
-
Nitriles
-
Phenylthiohydantoin / analogs & derivatives
-
Phenylthiohydantoin / therapeutic use
-
Positron Emission Tomography Computed Tomography*
-
Prostatic Neoplasms, Castration-Resistant / diagnostic imaging*
-
Prostatic Neoplasms, Castration-Resistant / drug therapy
-
Prostatic Neoplasms, Castration-Resistant / pathology
-
Radiopharmaceuticals
-
Urea / analogs & derivatives
Substances
-
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
-
Antineoplastic Agents
-
Benzamides
-
Nitriles
-
Radiopharmaceuticals
-
Phenylthiohydantoin
-
Urea
-
enzalutamide
-
Lysine